预防痴呆症的多领域干预:取得的成就,挑战和未来的前景
Takashi Sakurai1, Taiki Sugimoto1, Hidenori Arai1
1National Center for Geriatrics and Gerontology, Obu, Japan.
Geriatrics & gerontology international
|June 18, 2025
概括
通过针对多种风险因素,多领域干预措施在预防痴呆症方面表现有前途. 虽然结果各不相同,但最近的试验表明对老年人认知能力下降有好处,特别是在处理身体活动和营养方面.
科学领域:
- 老年学与公共卫生
- 神经科学与衰老问题
- 预防医学 预防医学
背景情况:
- 全球痴呆病例随着人口老龄化而上升,迫切需要采取预防策略.
- 针对可修改风险因素的多领域干预正在成为一个关键的方法.
- 现有研究为了解干预的有效性和挑战提供了基础.
研究的目的:
- 审查已完成和正在进行的痴呆症预防多领域干预试验.
- 确定当前的挑战和该领域的未来方向.
- 评估干预措施对认知结果和风险因素的影响.
主要方法:
- 2015年至今出版的多领域干预试验的系统审查.
- 分析认知结果和痴呆症风险因素 (例如体育活动,营养).
- 考虑影响试验成功的因素,包括COVID-19大流行.
主要成果:
- 来自2015-2019年试验的混合结果,没有注意到一致的认知改善.
- 在20世纪20年代的10项试验中,有7项报告了对认知结果的积极影响.
- 部分分析表明,痴呆症风险因素 (如身体不活动和营养) 的改善.
结论:
- 多领域干预措施显示出保护高危老年人免受认知衰退的潜力.
- 全球FINGERS网络旨在全球化和优化这些干预措施.
- 需要进一步发展社会实施,重点关注目标,交付,可扩展性和成本效益.
相关概念视频
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Cognitive Development During Adulthood
312
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
312
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42


